Glacis Technologies Partners with CHAI for AI Safeguard Standardization
In a significant development for the AI landscape in healthcare, Glacis Technologies has made strides towards enhancing transparency and trust by placing its open standard, OVERT (Observable Verification Evidence for Runtime Trust), under the stewardship of the Coalition for Health AI (CHAI) and the AIGovOps Foundation. This partnership aims to address the ever-increasing need for clear metrics and verifiable evidence of AI operations within healthcare systems.
The announcement, made on September 21, 2026, highlights an agreement that fosters shared stewardship of OVERT, which was developed to provide operational evidence from AI systems. The significant role of CHAI, coupled with its expertise in healthcare, underscores the importance of tailoring the OVERT standard to meet industry-specific requirements and expectations.
OVERT is designed as an open technical specification that allows for independent verification of AI actions within predetermined scopes. This innovative approach addresses the need for organizations to understand how AI systems function, particularly as these systems evolve from simple data retrieval to making critical healthcare decisions. As stated by Joe Braidwood, founder and CEO of Glacis Technologies, "We wrote OVERT because we saw a proof gap in how critical AI safeguards are monitored, especially in healthcare." By developing OVERT, the aim was to offer a resource accessible to all entities in the healthcare industry, including potential competitors.
The collaboration extends to the practical applications of OVERT in real-world scenarios. For healthcare organizations looking to implement AI workflows, OVERT provides a structured method to document whether essential criteria—such as authorizations, data boundaries, and clinician reviews—were met prior to an AI's operation. This evidence can subsequently be reviewed, thereby enabling organizations to uphold both security and regulatory standards.
Another prominent figure in this partnership, Ken Johnston, co-founder of the AIGovOps Foundation, elaborated on the operationalization of governance through technology. He emphasized that "Governance that lives in a document cannot be checked. Governance that runs as code can." With OVERT, practitioners will have access to a unified means of demonstrating that specified controls were executed within AI operations, paving the way for greater accountability and compliance across the board.
Brenton Hill, Head of Operations and General Counsel at CHAI, echoed this sentiment, highlighting the implications for healthcare organizations. He noted that the initiative to steward OVERT embodies a transparent methodology for delivering decision-level evidence—an essential requirement across various healthcare contexts. By inviting scrutiny and input from the broader community, CHAI endeavors to refine OVERT and affirm its relevance to contemporary healthcare environments.
It's crucial to understand that while OVERT establishes a voluntary technical specification for evidence generated from AI actions, it does not impose regulatory or legal obligations on organizations. Organizations remain responsible for their governance and must align their operations with applicable laws and regulations. Thus, the collaboration between Glacis, CHAI, and AIGovOps does not create a surveillance network or substitute for market oversight.
This joint effort marks a forward-thinking stride toward operational transparency in AI. For stakeholders interested in understanding the intricate functionality of AI within clinical workflows, OVERT offers a promising framework. To learn more about OVERT, its governance model, and guidance for implementation, interested parties can visit overt.is.
In sum, the partnership between Glacis Technologies, CHAI, and the AIGovOps Foundation represents a pivotal moment in the effort to standardize the verification processes for AI systems in healthcare, offering vital support for organizations keen on enhancing their AI governance practices.
The announcement, made on September 21, 2026, highlights an agreement that fosters shared stewardship of OVERT, which was developed to provide operational evidence from AI systems. The significant role of CHAI, coupled with its expertise in healthcare, underscores the importance of tailoring the OVERT standard to meet industry-specific requirements and expectations.
OVERT is designed as an open technical specification that allows for independent verification of AI actions within predetermined scopes. This innovative approach addresses the need for organizations to understand how AI systems function, particularly as these systems evolve from simple data retrieval to making critical healthcare decisions. As stated by Joe Braidwood, founder and CEO of Glacis Technologies, "We wrote OVERT because we saw a proof gap in how critical AI safeguards are monitored, especially in healthcare." By developing OVERT, the aim was to offer a resource accessible to all entities in the healthcare industry, including potential competitors.
The collaboration extends to the practical applications of OVERT in real-world scenarios. For healthcare organizations looking to implement AI workflows, OVERT provides a structured method to document whether essential criteria—such as authorizations, data boundaries, and clinician reviews—were met prior to an AI's operation. This evidence can subsequently be reviewed, thereby enabling organizations to uphold both security and regulatory standards.
Another prominent figure in this partnership, Ken Johnston, co-founder of the AIGovOps Foundation, elaborated on the operationalization of governance through technology. He emphasized that "Governance that lives in a document cannot be checked. Governance that runs as code can." With OVERT, practitioners will have access to a unified means of demonstrating that specified controls were executed within AI operations, paving the way for greater accountability and compliance across the board.
Brenton Hill, Head of Operations and General Counsel at CHAI, echoed this sentiment, highlighting the implications for healthcare organizations. He noted that the initiative to steward OVERT embodies a transparent methodology for delivering decision-level evidence—an essential requirement across various healthcare contexts. By inviting scrutiny and input from the broader community, CHAI endeavors to refine OVERT and affirm its relevance to contemporary healthcare environments.
It's crucial to understand that while OVERT establishes a voluntary technical specification for evidence generated from AI actions, it does not impose regulatory or legal obligations on organizations. Organizations remain responsible for their governance and must align their operations with applicable laws and regulations. Thus, the collaboration between Glacis, CHAI, and AIGovOps does not create a surveillance network or substitute for market oversight.
This joint effort marks a forward-thinking stride toward operational transparency in AI. For stakeholders interested in understanding the intricate functionality of AI within clinical workflows, OVERT offers a promising framework. To learn more about OVERT, its governance model, and guidance for implementation, interested parties can visit overt.is.
In sum, the partnership between Glacis Technologies, CHAI, and the AIGovOps Foundation represents a pivotal moment in the effort to standardize the verification processes for AI systems in healthcare, offering vital support for organizations keen on enhancing their AI governance practices.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.